AHA Letter to HHS Secretary Becerra on 340B Eligibility

March 31, 2021

AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).

We specifically request a waiver of certain 340B program eligibility criteria for 340B hospitals enrolled during the PHE that may have experienced a temporary change in payer mix due to the COVID-19 pandemic.

View the entire letter under Key Resources. 

Related Resources

Letter/Comment
Public
AHA letter to Senators, John Thune, Rob Portman, Shelley Moore Capito, Tammy Baldwin, Debbie Stabenow and Ben Cardin expressing support for legislation, S. 773.
Fact Sheets
Public
For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Fact Sheets
Public
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B…
Special Bulletin
Public
At A Glance The Health Resources and Services Administration (HRSA) Dec. 10 released its long-awaited final rule implementing an Affordable Care Act (ACA)…
Special Bulletin
Public
At A Glance The Centers for Medicare & Medicaid Services (CMS) yesterday released the calendar year (CY) 2021 outpatient prospective payment system (…
Special Bulletin
Public
The Centers for Medicare & Medicaid Services (CMS) Nov. 20 released an interim final rule implementing the Most Favored Nation (MFN) Model, a new payment…